Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha-synuclein and transgenic mouse models.

Pierre-Olivier Fernagut1, Marie-Françoise Chesselet

  • 1Departments of Neurology and Neurobiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1769, USA.

Neurobiology of Disease
|October 12, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenotypic characterization of an Atp13a2 knockout rat model of Parkinson's disease.

NPJ Parkinson's disease·2025
Same author

Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies known and novel cross-population and ancestry-specific associations as novel risk loci for Alzheimer's disease.

Genome biology·2025
Same author

Alpha-synuclein-induced nigrostriatal degeneration and pramipexole treatment disrupt frontostriatal plasticity.

NPJ Parkinson's disease·2024
Same author

Nigral ATP13A2 depletion induces Parkinson's disease-related neurodegeneration in a pilot study in non-human primates.

NPJ Parkinson's disease·2024
Same author

Dysfunction of striatal parvalbumin interneurons drives motor stereotypies in Cntnap2-/- mouse model of autism spectrum disorders.

PNAS nexus·2024
Same author

Recent Advances in Clinical Trials in Multiple System Atrophy.

Current neurology and neuroscience reports·2024

Alpha-synuclein (alpha-syn) is central to Parkinson disease and related synucleinopathies. Transgenic models, while not causing neuronal death, offer insights into alpha-syn

Area of Science:

  • Neuroscience
  • Genetics
  • Pathology

Background:

  • Alpha-synuclein (alpha-syn) is a key component of Lewy bodies and implicated in familial Parkinson disease (PD).
  • Synucleinopathies are a class of neurodegenerative diseases characterized by alpha-syn aggregation.
  • Understanding alpha-syn's role is crucial for neurodegenerative disease research.

Purpose of the Study:

  • To review existing alpha-synuclein transgenic models.
  • To discuss their clinical relevance to synucleinopathies.
  • To explore their utility in understanding disease mechanisms.

Main Methods:

  • Literature review of alpha-synuclein transgenic models.
  • Analysis of model recapitulation of synucleinopathy features.
  • Evaluation of model utility for studying alpha-syn's pathogenic role.

Related Experiment Videos

Main Results:

  • Multiple alpha-synuclein transgenic models exist.
  • These models exhibit some synucleinopathy features but not dopaminergic neuronal death in the substantia nigra.
  • Models are valuable tools for investigating alpha-syn's role and interactions.

Conclusions:

  • Alpha-synuclein transgenic models are essential tools for synucleinopathy research.
  • They aid in studying the physiological and pathological functions of alpha-synuclein.
  • Further utilization of these models can advance understanding of neurodegenerative disease processes.